Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 3/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.35 |
| ▸ | ITGAL | P20701 | 3/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792595 | 0.92 | DPP4 (0.37) | PREPDPP4PIK3CA | |
| SCHEMBL13228840 | 0.92 | DPP4 (0.37) | PREPDPP4PIK3CA | |
| SCHEMBL13228841 | 0.90 | SCN9A (0.34) | PREPERN1 | |
| SCHEMBL3790496 | 0.90 | SCN9A (0.34) | PREPERN1 | |
| SCHEMBL3791005 | 0.85 | KDM4E (0.36) | — | |
| SCHEMBL3797226 | 0.85 | DGAT1 (0.42) | ITGB2ICAM1ITGALDGAT1LOXL2 | |
| SCHEMBL3687351 | 0.81 | ERN1 (0.40) | ERN1 | |
| SCHEMBL13228818 | 0.81 | P2RX7 (0.43) | — | |
| SCHEMBL13261607 | 0.80 | ERN1 (0.35) | ERN1 | |
| SCHEMBL3789709 | 0.78 | ERN1 (0.35) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | ITGB2 4359/4885ICAM1 4397/4885ITGAL 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.